(Q42999127)

English

Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels

scientific article published in March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels (English)

1 reference

Europe PubMed Central

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

E J Bini

1

1 reference

Europe PubMed Central

12 November 2017

S Mehandru

2

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

12 November 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

12 November 2017

23

1 reference

Europe PubMed Central

12 November 2017

777-785

1 reference

Europe PubMed Central

12 November 2017

6

1 reference

Europe PubMed Central

12 November 2017

Hepatitis C infection and the patient with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Treatment of patients with hepatitis C and normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Hepatitis C in African Americans: summary of a workshop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02819.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2006.02819.X

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42999127&oldid=1976321592"